DOT1L and myelodysplastic syndrome: Like the HMTs EZH2 and DOT1L, the HDM LSD1 is also correlated with tumor onset and progression, and some inhibitors of LSD1, including GSK2879552 and INCB059872, are under investigation in different phases of pre-clinical and clinical trials for application in the treatment of AML, MDS, and NSCLC [13].